当前针对呼吸道合胞病毒感染的抗病毒疗法及有前景的候选药物。
Current antiviral therapies and promising drug candidates against respiratory syncytial virus infection.
作者信息
Feng Ziheng, Xie Zhengde, Xu Lili
机构信息
Key Laboratory of Major Diseases in Children, Ministry of Education, National Clinical Research Center for Respiratory Diseases, National Key Discipline of Pediatrics (Capital Medical University), Beijing Pediatric Research Institute, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing 100045, China; Research Unit of Critical Infection in Children, Chinese Academy of Medical Sciences, Beijing 100045, China.
Key Laboratory of Major Diseases in Children, Ministry of Education, National Clinical Research Center for Respiratory Diseases, National Key Discipline of Pediatrics (Capital Medical University), Beijing Pediatric Research Institute, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing 100045, China; Research Unit of Critical Infection in Children, Chinese Academy of Medical Sciences, Beijing 100045, China.
出版信息
Virol Sin. 2025 Apr;40(2):147-156. doi: 10.1016/j.virs.2025.01.003. Epub 2025 Jan 28.
Respiratory syncytial virus (RSV) is one of the most common viruses leading to lower respiratory tract infections (LRTIs) in children and elderly individuals worldwide. Although significant progress in the prevention and treatment of RSV infection was made in 2023, with two anti-RSV vaccines and one monoclonal antibody approved by the FDA, there is still a lack of postinfection therapeutic drugs in clinical practice, especially for the pediatric population. In recent years, with an increasing understanding of the pathogenic mechanisms of RSV, drugs and drug candidates, have shown great potential for clinical application. In this review, we categorize and discuss promising anti-RSV drug candidates that have been in preclinical or clinical development over the last five years.
呼吸道合胞病毒（RSV）是全球儿童和老年人下呼吸道感染（LRTIs）最常见的病毒之一。尽管2023年在RSV感染的预防和治疗方面取得了重大进展，有两种抗RSV疫苗和一种单克隆抗体获得了美国食品药品监督管理局（FDA）的批准，但临床实践中仍缺乏感染后治疗药物，尤其是针对儿科人群。近年来，随着对RSV致病机制的认识不断加深，药物及候选药物已显示出巨大的临床应用潜力。在本综述中，我们对过去五年中处于临床前或临床开发阶段的有前景的抗RSV候选药物进行分类和讨论。
Zotero 插件